NASDAQ:VRNA VERONA PHARMA P/S Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding VERONA PHARMA P/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.52 -0.05 (-0.76 %) (As of 09/22/2020 03:59 PM ET) Add Compare Share Today's Range$6.52Now: $6.52▼$6.6550-Day Range$6.55MA: $7.31▼$8.5052-Week Range$2.01Now: $6.52▼$15.71Volume72 shsAverage Volume675,920 shsMarket Capitalization$85.84 millionP/E RatioN/ADividend YieldN/ABeta0.35 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingVERONA PHARMA P/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.75, VERONA PHARMA P/S has a forecasted upside of 248.9% from its current price of $6.52.Amount of Analyst CoverageVERONA PHARMA P/S has only been the subject of 3 research reports in the past 90 days. Previous Next 3.5 Community Rank Outperform VotesVERONA PHARMA P/S has received 277 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVERONA PHARMA P/S has received 119 “underperform” votes. (Add your “underperform” vote.)Community SentimentVERONA PHARMA P/S has received 69.95% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about VERONA PHARMA P/S and other stocks. Vote “Outperform” if you believe VRNA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VRNA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVERONA PHARMA P/S does not currently pay a dividend.Dividend GrowthVERONA PHARMA P/S does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VERONA PHARMA P/S insiders have not sold or bought any company stock.Percentage Held by Institutions54.51% of the stock of VERONA PHARMA P/S is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for VERONA PHARMA P/S are expected to grow in the coming year, from ($1.36) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of VERONA PHARMA P/S is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VERONA PHARMA P/S is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVERONA PHARMA P/S has a P/B Ratio of 1.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.73 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VRNA Previous Symbol CUSIPN/A CIK1657312 Webwww.veronapharma.com Phone44-20-3283-4200Debt Debt-to-Equity Ratio0.04 Current Ratio2.99 Quick Ratio2.99Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.28 per share Price / Book1.99Profitability EPS (Most Recent Fiscal Year)($3.10) Net Income$-40,780,000.00 Net MarginsN/A Return on Equity-115.93% Return on Assets-73.68%Miscellaneous Employees22 Outstanding Shares13,166,000Market Cap$85.84 million Next Earnings Date11/3/2020 (Estimated) OptionableNot Optionable $6.52 -0.05 (-0.76 %) (As of 09/22/2020 03:59 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive VRNA News and Ratings via Email Sign-up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter. VERONA PHARMA P/S (NASDAQ:VRNA) Frequently Asked Questions How has VERONA PHARMA P/S's stock been impacted by Coronavirus (COVID-19)? VERONA PHARMA P/S's stock was trading at $4.84 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VRNA stock has increased by 34.7% and is now trading at $6.52. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of VERONA PHARMA P/S? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VERONA PHARMA P/S in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for VERONA PHARMA P/S. When is VERONA PHARMA P/S's next earnings date? VERONA PHARMA P/S is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for VERONA PHARMA P/S. How were VERONA PHARMA P/S's earnings last quarter? VERONA PHARMA P/S (NASDAQ:VRNA) issued its quarterly earnings data on Friday, August, 14th. The company reported ($0.68) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.28. View VERONA PHARMA P/S's earnings history. What price target have analysts set for VRNA? 4 brokers have issued 12 month target prices for VERONA PHARMA P/S's stock. Their forecasts range from $17.00 to $34.00. On average, they anticipate VERONA PHARMA P/S's share price to reach $22.75 in the next twelve months. This suggests a possible upside of 248.9% from the stock's current price. View analysts' price targets for VERONA PHARMA P/S. Are investors shorting VERONA PHARMA P/S? VERONA PHARMA P/S saw a decrease in short interest in August. As of August 31st, there was short interest totaling 6,700 shares, a decrease of 89.7% from the August 15th total of 65,200 shares. Based on an average trading volume of 1,680,000 shares, the days-to-cover ratio is presently 0.0 days. View VERONA PHARMA P/S's Short Interest. Who are some of VERONA PHARMA P/S's key competitors? Some companies that are related to VERONA PHARMA P/S include Merus (MRUS), AMAG Pharmaceuticals (AMAG), Catalyst Pharmaceuticals (CPRX), Aeglea Bio Therapeutics (AGLE), CytomX Therapeutics (CTMX), IMV (IMV), Xeris Pharmaceuticals (XERS), Concert Pharmaceuticals (CNCE), Aquestive Therapeutics (AQST), Agile Therapeutics (AGRX), Chiasma (CHMA), Urovant Sciences (UROV), Paratek Pharmaceuticals (PRTK), VYNE Therapeutics (VYNE) and Osmotica Pharmaceuticals (OSMT). View all competitors. What other stocks do shareholders of VERONA PHARMA P/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other VERONA PHARMA P/S investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Pfizer (PFE), Novavax (NVAX), SCYNEXIS (SCYX), Vaxart (VXRT), Abbott Laboratories (ABT), Citius Pharmaceuticals (CTXR) and electroCore (ECOR). Who are VERONA PHARMA P/S's key executives? VERONA PHARMA P/S's management team includes the following people: Dr. Jan-Anders Karlsson, CEO & Exec. Director (Age 64)Mr. Piers John Morgan, Chief Financial Officer (Age 53)Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA, Gen. Counsel (Age 52)Ms. Victoria Stewart, Director of CommunicationsDr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 57) When did VERONA PHARMA P/S IPO? (VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers. What is VERONA PHARMA P/S's stock symbol? VERONA PHARMA P/S trades on the NASDAQ under the ticker symbol "VRNA." Who are VERONA PHARMA P/S's major shareholders? VERONA PHARMA P/S's stock is owned by many different institutional and retail investors. Top institutional investors include D.A. Davidson & CO. (0.89%) and Wedbush Securities Inc. (0.83%). Which institutional investors are buying VERONA PHARMA P/S stock? VRNA stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., and D.A. Davidson & CO.. How do I buy shares of VERONA PHARMA P/S? Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is VERONA PHARMA P/S's stock price today? One share of VRNA stock can currently be purchased for approximately $6.52. How big of a company is VERONA PHARMA P/S? VERONA PHARMA P/S has a market capitalization of $85.84 million. The company earns $-40,780,000.00 in net income (profit) each year or ($3.10) on an earnings per share basis. VERONA PHARMA P/S employs 22 workers across the globe. What is VERONA PHARMA P/S's official website? The official website for VERONA PHARMA P/S is www.veronapharma.com. How can I contact VERONA PHARMA P/S? VERONA PHARMA P/S's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 44-20-3283-4200 or via email at [email protected] This page was last updated on 9/22/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
